Clinical trials: Stomach Cancer Recurrent
- Condition Stomach Cancer Recurrent
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers
The purpose of this study is to determine whether CRS-207 in combination with pembrolizumab is safe and effective in adults with recurrent or metastatic gastric, gastroesophageal junction, or esophageal cancer who have received…
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT03122548
- Testing
- CRS-207, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 5 people
- Sponsor
- Aduro Biotech, Inc.
Gastric Cancer
Safety and Efficacy of Trastuzumab BS
To confirm the safety and efficacy of this drug under the actual use
- Trial name
- NCT04181333
- Testing
- TRASTUZUMAB BS
- Where
- Japan
- Volunteers
- 8 people
- Sponsor
- Pfizer
Gastric Cancer
Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients
To assess the efficacy of olaparib when given in combination with paclitaxel compared with paclitaxel alone as defined by progression-free survival (PFS), in all patients with recurrent and metastatic gastric cancer who progress…
- Trial name
- NCT01063517
- Testing
- olaparib, paclitaxel
- Where
- 7 sites in South Korea
- Volunteers
- 124 people
- Sponsor
- AstraZeneca
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
This study was conducted to advance new treatment for patients with metastatic or locally advanced cancers expressing Neurotensin receptor 1 (NTSR1).
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Gastric Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT03525392
- Testing
- 177Lu-3BP-227 (also called 177Lu-IPN01087)
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 14 people
- Sponsor
- Ipsen
Gastric Cancer
Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)
The purpose of this study is to estimate objective response rates (ORRs) of pembrolizumab + oxaliplatin + TS-1 and pembrolizumab + cisplatin + TS-1, as first-line treatment for gastric cancer in programmed death-ligand 1 (PD-L1)…
- Trial name
- NCT03382600
- Testing
- Pembrolizumab, Oxaliplatin, TS-1
- Where
- 25 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastric Cancer
Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer
Study H3E-MW- S108 is a multicenter, single arm, open-label Phase 2 study to determine the response rate of pemetrexed plus cisplatin in patients with Stage IV gastric cancer, not amenable to curative surgery, or recurrence after…
- Trial name
- NCT00415168
- Testing
- pemetrexed, cisplatin
- Where
- 6 sites in Russia
- Volunteers
- 53 people
- Sponsor
- Eli Lilly and Company
Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma
Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC
This study will evaluate the safety and efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive solid tumors and in combination with pembrolizumab in patients with…
- Conditions
- Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV-Related Leiomyosarcoma, EBV Related Carcinoma
- Trial name
- NCT05166577
- Testing
- Nanatinostat, Valganciclovir, Pembrolizumab
- Where
- 13 sites in United States, Australia and 6 more
- Volunteers
- 26 people
- Sponsor
- Viracta Therapeutics, Inc.
Stomach Neoplasms
An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy
The study consisted of two parts. In Part 1 the study enrolled 38 patients (Step 1 Simon 2 step design) after which Step 2 was opened and the total enrollment target for the study (n=63) was exceeded due to a rapid enrollment (78…
- Trial name
- NCT00226811
- Testing
- Sunitinib
- Where
- 18 sites in China, Hong Kong and 5 more
- Volunteers
- 78 people
- Sponsor
- Pfizer
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)
This is a study of pembrolizumab (MK-3475) for advanced gastric or gastroesophageal junction adenocarcinoma; pembrolizumab will be given as monotherapy to participants who have had previous treatment or who are treatment-naïve…
- Trial name
- NCT02335411
- Testing
- pembrolizumab, cisplatin, 5-FU
- Volunteers
- 318 people
- Sponsor
- Merck Sharp & Dohme LLC
Adenocarcinoma of the Stomach, Gastroesophageal Junction Expressing Guanylyl Cyclase C
A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction
The purpose of this study is to assess the efficacy, safety and tolerability of MLN0264 in patients with recurrent or metastatic guanylyl cyclase C (GCC)-positive adenocarcinoma of the stomach or gastroesophageal junction.
- Trial name
- NCT02202759
- Testing
- MLN0264
- Where
- 17 sites in United States, Belgium and 2 more
- Volunteers
- 38 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Stomach Neoplasms
Docetaxel and Oxaliplatin in Gastric Cancer
This phase II study addressed the use of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced…
- Trial name
- NCT00382720
- Testing
- Docetaxel + Oxaliplatin, Docetaxel + Oxaliplatin + 5-FU, Docetaxel + Oxaliplatin + Capecitabine
- Where
- 12 sites in United States, Belgium and 10 more
- Volunteers
- 275 people
- Sponsor
- Sanofi
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
The purpose of this study was to demonstrate superiority of treatment with avelumab plus best supportive care (BSC) versus physician's choice (chosen from a pre-specified list of therapeutic options) plus BSC.
- Trial name
- NCT02625623
- Testing
- Avelumab, Irinotecan, Paclitaxel
- Where
- 75 sites in United States, Australia and 8 more
- Volunteers
- 371 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.